Laurent Chouchana
Overview
Explore the profile of Laurent Chouchana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chouchana L, Collier M, Martin C, Burgel P, Treluyer J
J Cyst Fibros
. 2025 Mar;
PMID: 40058987
Objectives: Recent therapeutic advances, mainly with the advent of CFTR modulators, have been associated with an increasing number of pregnancies in females with cystic fibrosis (fwCF). This study aimed to...
2.
Collier M, Chouchana L, Frange P, Sibiude J, Munnich A, Treluyer J, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39905585
Background: The health of children exposed but uninfected by human immunodeficiency virus (HIV) requires long-term assessment, in particular in terms of neurological and cognitive development. Numerous confounding factors have hampered...
3.
Henry A, Santulli P, Bourdon M, Maignien C, Chapron C, Treluyer J, et al.
Hum Reprod Open
. 2025 Jan;
2025(1):hoae072.
PMID: 39807112
Study Question: Is there an association between dydrogesterone exposure during early pregnancy and the reporting of birth defects? Summary Answer: This observational analysis based on global safety data showed an...
4.
Tisseyre M, Collier M, Beeker N, Kaguelidou F, Treluyer J, Chouchana L
Drug Saf
. 2024 Dec;
48(3):265-277.
PMID: 39630354
Introduction And Objective: Proton pump inhibitor (PPI) use in children increases the risk of infections, prompting inquiry into the impact of prenatal PPIs exposure on serious infections in offspring. As...
5.
Schiro P, Barus R, Chouchana L, Sari R, Cougoul P, Montastruc F, et al.
Therapie
. 2024 Oct;
PMID: 39482118
No abstract available.
6.
Verdaguer J, Chouchana L, Robert M, Bergeron S, Montastruc F, Barus R
Therapie
. 2024 Oct;
PMID: 39438243
Objectives: Fluoropyrimidine-based therapies, 5-fluorouracil (5-FU) and its oral prodrugs, capecitabine and tegafur/oteracil/gimeracil (S-1), are pivotal drugs to treat gastric cancer. Fluoropyrimidines are associated with cardiotoxicity including ischemic cardiopathy. The mechanisms...
7.
Pinson P, Boussaid I, Decroocq J, Chouchana L, Birsen G, Barrois M, et al.
Lancet Haematol
. 2024 Oct;
11(11):e850-e861.
PMID: 39389070
Background: Pregnancy-associated haematological malignancy is a rare event; therefore, data available to guide the treatment are scarce. We aimed to evaluate the incidence, overall survival, and maternal morbidity and mortality...
8.
Garey J, Damkier P, Scialli A, Lusskin S, Braddock S, Chouchana L, et al.
Birth Defects Res
. 2024 Aug;
116(8):e2392.
PMID: 39189597
On January 12, 2024 the safety committee of the European Medicines Agency (EMA) recommended precautionary measures over a potential risk of neurodevelopmental disorders in children born to men treated with...
9.
Ayme-Dietrich E, Kaguelidou F, Bertschy G, Chouchana L
Pharmacoepidemiol Drug Saf
. 2024 Jun;
33(6):e5814.
PMID: 38837561
Introduction: Methylphenidate (MPH) is a common treatment of attention-deficit/hyperactivity disorder (ADHD). Concern has been raised regarding its cardiovascular safety, partly in relation with its micromolar affinity for the 5-HT receptor,...
10.
Boukhlal S, Chouchana L, Saadi M, Casadevall M, Cohen P, Dunogue B, et al.
Semin Arthritis Rheum
. 2024 May;
67:152469.
PMID: 38781783
Objectives: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence and determinants of DDI and...